Kane Biotech completes submission for wound cleanser

Dr. Robert Huizinga reports KANE BIOTECH COMPLETES U.S. FDA 510(K) SUBMISSION FOR REVYVE ANTIMICROBIAL WOUND CLEANSER Kane Biotech Inc. has completed a U.S. Food and Drug Administration 510(k) clearance submission for its revyve anti-microbial wound cleanser. revyve anti-microbial wound cleanser is the company's third product in its revyve product line and complementary to Kane's revyve anti-microbial wound gel and anti-microbial wound gel spray products. This new companion product will be part of routine wound management, providing irrigation for the purpose of cleansing acute and chronic wounds to decrease the bacterial load and remove loose material. The formulation of the cleanser is based on the revyve anti-microbial wound gel. The annual U.S. market size for wound cleansers exceeded $200-million (U.S.) in 2024. About Kane Biotech Inc. Kane Biotech is developing novel wound care treatments that disrupt biofilms and transform healing outcomes. Biofilms are one of the main contributors to antibiotic resistance in wounds, which results in serious clinical outcomes and significant cost. revyve addresses both biofilms and wound bacteria. revyve anti-microbial wound gel and revyve anti-microbial wound gel spray are U.S. FDA 510(k) cleared. revyve anti-microbial wound gel is Health Canada approved. We seek Safe Harbor.